

Committee Reports. Reports from Council committees on their work for 1996.

Open Forum—Emerging Issues: Internet and Home Banking. (Tentative) Committee reports concerning emerging issues and trends, focusing on the Internet and home banking.

Other matters previously considered by the Council or initiated by Council members also may be discussed.

Persons wishing to submit to the Council their views regarding any of the above topics may do so by sending written statements to Deanna Aday-Keller, Secretary, Consumer Advisory Council, Division of Consumer and Community Affairs, Board of Governors of the Federal Reserve System, Washington, D.C. 20551.

Information with regard to this meeting may be obtained from Ms. Aday-Keller, 202-452-6470. Telecommunications Device for the Deaf (TDD) users may contact Dorothea Thompson, 202-452-3544.

Board of Governors of the Federal Reserve System, September 26, 1996.

William W. Wiles

Secretary of the Board

[FR Doc. 96-25184 Filed 10-1-96; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Institute for Occupational Safety and Health

In accordance with section 10(a)(2) of the Federal Advisory Committee Act

(Pub. L. 92-463), the National Institute for Occupational Safety and Health, of the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Board of Scientific Counselors, National Institute for Occupational Safety and Health (BSC, NIOSH).

Time and Date: 10 a.m.-5 p.m., October 18, 1996.

Place: NIOSH Research Laboratory, 1095 Willowdale Road, Morgantown, West Virginia 26505.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people.

Purpose: The Board reviews research activities to provide guidance on the quality, timeliness, and efficacy of the Institute's programs.

Matters To Be Discussed: Agenda items include a report from the Director of NIOSH, the Musculoskeletal Program Evaluation, Extramural Activities, National Occupational Research Agenda, Health Hazard Evaluation Program Evaluation, EPA Science Advisory Board Communications, and future activities of the Board.

Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Bryan D. Hardin, Ph.D., Acting Executive Secretary, BSC, NIOSH, CDC, 1600 Clifton Road, NE, M/S D-35, Atlanta, Georgia 30333, telephone 404/639-3773.

Dated: September 26, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96-25169 Filed 10-1-96; 8:45 am]

BILLING CODE 4163-19-M

Food and Drug Administration

[Docket No. 96N-0340]

Lilly Research Laboratories, et al.; Withdrawal of Approval of 12 New Drug Applications, 8 Abbreviated Antibiotic Applications, and 23 Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 12 new drug applications (NDA's), 8 abbreviated antibiotic applications (AADA's), and 23 abbreviated new drug applications (ANDA's). The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

EFFECTIVE DATE: October 2, 1996.

FOR FURTHER INFORMATION CONTACT:

Olivia A. Vieira, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1046.

SUPPLEMENTARY INFORMATION: The holders of the applications listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing.

Application no.	Drug	Applicant
NDA 6-470	Calcium Gluceptate	Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285.
NDA 8-826	Chlor-Trimeton Injection	Schering Corp., 2000 Galloping Hill Rd., Kenilworth, NJ 07033.
NDA 9-585	Cort-Dome (hydrocortisone, cream) Cream, 1/2%, 1%	Bayer Pharmaceutical, 400 Morgan Ln., West Haven, CT 06516-4175.
NDA 11-284	Meprospan (meprobamate) Capsules, 200 milligrams (mg) and 400 mg.	Wallace Laboratories, Half Acre Rd., P.O. Box 1001, Cranbury, NJ 08512-0181.
NDA 16-049	Innovar (fentanyl citrate/droperidol) for Injection	Janssen Pharmaceutica, 1125 Trenton-Harbourton Rd., P.O. Box 200 Titusville, NJ 08560-0200.
NDA 17-589	Solatene (betacarotene) Capsules	Hoffmann-LaRoche Inc., 340 Kingsland St., Nutley, NJ 07110-1199.
NDA 18-669	Niclocide (niclosamide) Tablets	Bayer Pharmaceutical.
NDA 18-806	Indomethacin Capsules, 25 mg and 50 mg	Warner Chilcott Laboratories, 200 Plymouth Rd., Ann Arbor, MI 48105.
NDA 18-830	Tambocor (flecainide acetate) 50, 100, 150 and 200 mg Tablets.	3M Pharmaceuticals, 3M Center, Bldg. 270-3A-01, St. Paul, MN 55144-1000.
NDA 19-329	Sodium Chloride Injection 23.4%	Fujisawa USA, Inc., Parkway North Center, Three Parkway North, Deerfield, IL 60015-2548.
NDA 50-550	Moxan (moxalactam disodium)	Lilly Research Laboratories.
NDA 50-565	Coatin (amdinocillin)	Hoffman-LaRoche, Inc.
AADA 60-107	Sterile Streptomycin Sulfate	Lilly Research Laboratories.

Application no.	Drug	Applicant
AADA 60-384	Penicillin G Potassium for Injection (buffered)	Do.
AADA 60-385	Neomycin Sulfate Tablets, 500 mg (eq. 350 mg base)	Do.
AADA 60-403	Penicillin G Potassium Tablets	Do.
AADA 60-404	Streptomycin Sulfate Injection	Do.
AADA 60-601	Penicillin G Potassium for Injection	Do.
AADA 60-687	Bacitracin Ophthalmic Ointment, 500 units/gram	Do.
AADA 61-742	Sterile Cefazolin Sodium, vials	Fujisawa Pharmaceuticals Co., Ltd., 1515 Fairway, Rydal Park 181 Woodside, Rydal, PA 19046-1664.
ANDA 70-591	Ibuprofen Tablets, 200 mg	Bayer Corp. 36 Columbia Rd., Morristown, NJ 07962-1910.
ANDA 70-626	Ibuprofen Capsules, 200 mg	Do.
ANDA 71-001	Ibuprofen Tablets, 200 mg	Do.
ANDA 71-002	Ibuprofen Capsules, 200 mg	Do.
ANDA 71-508	Oxazepam Tablets, 15 mg	Warner Chilcott.
ANDA 71-767	Flurazepam Hydrochloride Capsules, 15 mg	Do.
ANDA 71-768	Flurazepam Hydrochloride Capsules, 30 mg	Do.
ANDA 72-138	Clonidine Hydrochloride Tablets, 0.1 mg	Do.
ANDA 72-139	Clonidine Hydrochloride Tablets, 0.2 mg	Do.
ANDA 72-140	Clonidine Hydrochloride Tablets, 0.3 mg	Do.
ANDA 80-419	Hydrocortisone Acetate Cream, 1%	H. R. Cenci Laboratories, Inc., P.O. Box 12524, Fresno, CA 93778-2524.
ANDA 83-632	Isoniazid Tablets, 50 mg	Halsey Drug Co., Inc., 1827 Pacific St., Brooklyn, NY 11233-3599.
ANDA 85-501	Phentermine Hydrochloride Capsules, 8 mg	Lemmon Co., 650 Cathill Rd., Sellersville, PA 18960.
ANDA 85-502	Theophylline Anhydrous Oral Suspension, 100 mg/5 milliliters (mL)	Forest Laboratories, Inc., 909 Third Ave., New York, NY 10022-4731.
ANDA 85-924	Amitriptyline Hydrochloride Tablets, 150 mg	Halsey Drug Co., Inc.
ANDA 86-240	Kenalog-H® (Triamcinolone Acetonide) Cream 0.1%	Apothecon, P.O. Box 4500, Princeton, NJ 08543-4500.
ANDA 87-941	Diphenhydramine Hydrochloride Elixir, 12.5 mg/5 mL	H. R. Cenci Laboratories, Inc.
ANDA 88-303	Theophylline Elixir, 80 mg/15 mL	Do.
ANDA 88-304	Diphenhydramine Hydrochloride Elixir, 12.5 mg/5 mL	Do.
ANDA 88-654	Theophylline Extended-release Capsules, 125 mg	Central Pharmaceuticals, Inc., 120 East Third St., P.O. Box 328, Seymour, IN 47274-0328.
ANDA 89-013	Promethazine Plain Syrup (Promethazine Hydrochloride), 6.25 mg/5 mL	H. R. Cenci Laboratories, Inc.
ANDA 89-458	Glutethimide Tablets, 250 mg	Halsey Drug Co., Inc.
ANDA 89-568	Butalbital and Acetaminophen Tablets, 50 mg/325 mg	Do.

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the applications listed in the table in this document, and all amendments and supplements thereto, is hereby withdrawn, effective October 2, 1996.

Dated: September 10, 1996.

Janet Woodcock,

Director, Center for Drug Evaluation and Research.

[FR Doc. 96-25198 Filed 9-30-96; 8:45 am]

BILLING CODE 4160-01-F

Health Resources and Services Administration

Agency Information Collection Activities: Submission for OMB Review; Comment Request

Periodically, the Health Resources and Services Administration (HRSA) publishes abstracts of information collection requests under review by the Office of Management and Budget, in compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35). To request a copy of the clearance requests submitted to OMB for review, call the HRSA Reports Clearance Office on (301) 443-1129.

The following request has been submitted to the Office of Management and Budget for review under the Paperwork Reduction Act of 1995:

2. Annual Administrative Reports for Ryan White Comprehensive AIDS Resources Emergency (CARE) Act of 1990, Titles I and II—Extension and Revision—The Annual Administrative

Reports (AAR) are submitted by grantees funded under Titles I and II of the Ryan White CARE Act of 1990 (as amended by the CARE Act amendments of 1996) and include aggregate information about disbursement of funds, number of clients served and services provided, demographic information about clients served, and costs of provided services. Title I grantees include local governments that meet legislative criteria for disproportionate impact of AIDS. Title II grantees include the 50 States, the District of Columbia, and a small number of territories. Grantees obtain the information for the AAR from individual service providers. Automated reporting alternatives are available to grantees and to providers at the grantee's option. This information is used to determine whether the purposes of the Act and the grants made pursuant to it are being fulfilled. The information is also used locally for planning and priority setting. Respondents include state and local governments,